Alumis
ALMS
6.77
-0.16
-2.31%
Alumis
US · ALMS
#3337 by market cap
Listed 2024
6.77
-0.16
-2.31%
Live - 5344 symbols - heartbeat 285s ago
· 2026-10-08 09:18
Pre-market
6.88
+1.62%
After-hours
6.77
0.00%
Overnight
6.72
-0.74%
- Market cap
- 876.28M
- P/E (TTM)i
- -1.65
- P/Bi
- 1.94
- EPSi
- -2.86
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on ALMS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 4.6 percentage points.
Institutional ownership
- Held by institutions
- 92.27% -4.64pp
- Institutions
- 238 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund33.70%
VC/PE Fund30.01%
Hedge Fund26.27%
Public Company1.46%
Individual/Insider0.54%
Private Company0.42%
Government Pension Fund0.20%
Insurance Company0.17%
Other7.19%
Top holders as of 2026-06-30
Matrix Capital Management Company, LP
11.70% · 15.14M sh
Foresite Capital Management, LLC
7.09% · 9.18M sh
BlackRock
6.35% · 8.22M sh
Samsara BioCapital LLC
5.59% · 7.24M sh
FMR
5.23% · 6.77M sh
Deep Track Capital, LP
4.90% · 6.35M sh
T. Rowe Price Group, Inc.
4.02% · 5.20M sh
Vanguard Capital Management, LLC
3.73% · 4.83M sh
venBio LLC
3.50% · 4.53M sh
Nextech Invest Ltd.
2.74% · 3.54M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 41 buys · 9 sells
| Name | Role | Stake |
|---|---|---|
| Matrix Capital Management Company, LP | -- | 11.70% |
| David Goldstein | Chief Scientific Officer & Head of CMC | 0.18% |
| Roy Hardiman | Chief Business & Legal Officer | 0.15% |
| Martin Babler | Chairperson & CEO | 0.09% |
| Mark Bradley | Chief Development Officer | 0.05% |
| Jorn Drappa | Chief Medical Officer & Head of Research and Development | 0.03% |
| Zhengbin Yao | Independent Director | 0.02% |
| Alan Colowick | Independent Director | 0.01% |
| C. Machado | Independent Director | 0.01% |
| John Schroer | Chief Financial Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-07 | Samsara BioCapital LLC | -- | Open Market Acquisition | +986,721 | $10.63–11.17 |
| 2026-09-07 | Samsara BioCapital LLC | -- | Open Market Disposition | -96,131 | $10.55 |
| 2026-08-02 | Roy Hardiman | Chief Business & Legal Officer | Open Market Disposition | -2,692 | $26.37 |
| 2026-08-02 | John Schroer | Chief Financial Officer | Open Market Disposition | -3,282 | $26.37 |
| 2026-08-02 | David Goldstein | Chief Scientific Officer & Head of CMC | Open Market Disposition | -2,596 | $26.37 |
| 2026-08-02 | Jorn Drappa | Chief Medical Officer & Head of Research and Development | Open Market Disposition | -2,447 | $26.37 |
| 2026-08-02 | Sanam Pangali | Chief Legal Officer | Open Market Disposition | -1,364 | $26.37 |
| 2026-08-02 | Mark Bradley | Chief Development Officer | Open Market Disposition | -2,572 | $26.37 |
| 2026-07-05 | Sanam Pangali | Chief Legal Officer | Derivative Exercise and Sale | -5,000 | $5.06–28.00 |
| 2026-06-29 | Srinivas Akkaraju | Independent Director | Other Acquisition | +3,553 | -- |
| 2026-06-29 | Srinivas Akkaraju | Independent Director | Other Derivative Acquisition | +15,528 | $28.14 |
| 2026-06-29 | Sapna Srivastava | Independent Director | Other Acquisition | +3,553 | -- |
| 2026-06-29 | Sapna Srivastava | Independent Director | Other Derivative Acquisition | +15,528 | $28.14 |
| 2026-06-29 | Lynn Tetrault | Independent Director | Other Acquisition | +3,553 | -- |
| 2026-06-29 | Lynn Tetrault | Independent Director | Other Derivative Acquisition | +15,528 | $28.14 |
| 2026-06-29 | C. Machado | Independent Director | Other Acquisition | +3,553 | -- |
| 2026-06-29 | C. Machado | Independent Director | Other Derivative Acquisition | +15,528 | $28.14 |
| 2026-06-29 | Zhengbin Yao | Independent Director | Other Acquisition | +3,553 | -- |
| 2026-06-29 | Zhengbin Yao | Independent Director | Other Derivative Acquisition | +15,528 | $28.14 |
| 2026-05-21 | Jorn Drappa | Chief Medical Officer & Head of Research and Development | Derivative Exercise and Retained | +26,852 | $5.06–8.84 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:18:15 · For reference only, not investment advice and not tailored to your situation.